Lead sponsor
Yanbing Li
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
1
Active
324
Total enrollment
0
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
1
Trials by status
Not yet recruiting
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesBMI 20-35Ph 4Not yet recruiting324